Antimalarials

Cutaneous Lupus Erythematosus

Volumn , Issue , 2005, Pages 347-372

  Ochsendorf, Falk R ^a  

^a GOETHE UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 33645458259     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/3-540-26581-3_26     Document Type: Chapter

References (112)

1. American College of Rheumatology Ad Hoc Committee on Clinical Guidelines (1996) Guidelines for monitoring drug therapy in rheumatoid arthritis. Arthritis Rheum 39:723-731
2. Araiza-Casillas R, Cardenas F, Morales Y, Cardiel MH (2004) Factors associated with chloroquineinduced retinopathy in rheumatic diseases. Lupus 13:119-124
3. Arnal C, Piette JC, Leone J, Taillan B, Hachulla E, Roudot-Thoraval F, Papo T, Schaeffer A, Bierling P, Godeau B (2002) Treatment of severe immune thrombocytopenia associated with systemic lupus erythematosus: 59 cases. J Rheumatol 29:75-83
4. Asch PH, Caussade P, Marquart-Elbaz C, Boehm N, Grosshans E (1997) Chloroquine-induced achromotrichia. An ultrastructural study. Ann Dermatol Venereol 124:552-556
5. Avina-Zubieta JA, Galindo-Rodriguez S, Newman S, Suarez-Almazor ME, Russell AS (1998) Long-term effectiveness of antimalarial drugs in rheumatic diseases. Ann Rheum Dis 57:582-587
6. Baguet JP, Tremel F, Fabre M (1999) Chloroquine cardiomyopathy with conduction disorders. Heart 81:221-223
7. Barthel HR, Meier LG, Wallace DJ (1996) Antimalariamittel bei rheumatischen Erkrankungen. Dtsch medWschr 121:1576-1582
8. Bauer F (1981) Quinacrine hydrochloride drug eruption (tropical lichenoid dermatitis). Its early and late sequelae and its malignant potential. A review. J Am Acad Dermatol 4:239-248
9. Becerra-Cunat JL, Coll-Canti J, Gelpi-Mantius E, Ferrer-Avelli X, Lozano-Sanchez M, Millan-Torne M, Ojanguren I, Ariza A, Olive A 2003 Chloroquine-induced myopathy and neuropathy: progressive tetraparesis with areflexia that simulates a polyradiculoneuropathy. Two case reports. Rev Neurol 36:523-526
10. Benagiano G (2001) Non-surgical female sterilization with quinacrine: an update. Contraception 63:239-245
11. Bienfang D, Coblyn JS, Liang MH, Corzillius M (2000) Hydroxychloroquine retinopathy despite regular ophthalmologic evaluation: a consecutive series. J Rheumatol 27:2703-2706
12. Boelaert JR, Piette J, Sperber K (2001) The potential place of chloroquine in the treatment of HIV-1-infected patients. J Clin Virol 20:137-140
13. Borba EF, Bonfa E (2001) Longterm beneficial effect of chloroquine diphosphate on lipoprotein profile in lupus patients with and without steroid therapy. J Rheumatol 28:780-785
14. Borden MB, Parke AL (2001) Antimalarial drugs in systemic lupus erythematosus: use in pregnancy. Drug Saf 24:1055-1063
15. Callaway JL (1979) Late sequelae of quinacrine dermatitis, a new premalignant entity. J Am Acad Dermatol 1:456-457
16. Canadian Hydroxychloroquine Study Group (1991) A randomized study of the effect of withdrawing hydroxychloroquine sulfate in systemic lupus erythematosus. New Engl J Med 324:150-154
17. Canadian rheumatology association (2000) Canadian Consensus Conference on hydroxychloroquine. J Rheumatol 27:2919-2921
18. Carmichael SJ, Charles B, Tett SE (2003) Population pharmacokinetics of hydroxychloroquine in patients with rheumatoid arthritis. Ther Drug Monit 25:671-681
19. Chung HS, Hann SK (1997) Lupus panniculitis treated by a combination therapy of hydroxychloroquine and quinacrine. J Dermatol 24:569-572
20. Clegg DO, Dietz F, Duffy J, Willkens RF, Hurd E, Germain BF, Wall B, Wallace DJ, Bell CL, Sleckman J (1997) Safety and efficacy of hydroxychloroquine as maintenance therapy for rheumatoid arthritis after combination therapy with methotrexate and hydroxychloroquine. J Rheumatol 24:1896-1902
21. Clemessy JL, Taboulet P, Hoffmann JF, Hantson P, Barriot P, Bismuth C, Baud J (1996) Treatment of acute chloroquine poisoning: a 5-year experience. Critical Care Med 24:1189-1195
22. Costedoat-Chalumeau N, Amoura Z, Duhaut P, Huong du LT, Sebbough D, Wechsler B, Vauthier D, Denjoy I, Lupoglazoff JM, Piette JC 2003 Safety of hydroxychloroquine in pregnant patients with connective tissue diseases: a study of one hundred thirty-three cases compared with a controll group. Arthritis Rheum 48:3207-3211
23. D'Cruz D (2001) Antimalarial therapy: a panacea for mild lupus? Lupus 10:148-151
24. Dereure O, Guilhou JJ (2002) Eosinophilic-like erythema: a clinical subset of Well's eosinophilic cellulitis responding to antimalarial drugs? Ann Dermatol Venereol 129:720-723
25. Dubois EL (1976) Lupus erythematosus, 2nd edn. University of Southern California Press, Los Angeles, pp 548, 588
26. Ducharme J, Farinotti R (1996) Clinical pharmacokinetics and metabolism of chloroquine. Focus on recent advancements. Clin Pharmacokin 31:257-274
27. Dutz JP, Ho VC (1998) Immunosuppressive agents in dermatology: an update. Dermatol Clin 16:235-251
28. Easterbrook M (1985) The sensitivity of Amsler grid testing in early chloroquine retinopathy. Trans Opthalmol Soc UK 104:204-207
29. Engel GL, Romano J, Ferris Eb (1947) Effect of quinacrine on the central nervous system. Arch Neurol 58:337-350
30. Erkan D, Yazici Y, Peterson MG, Sammaritano L, Lockshin MD (2002) A cross-sectional study of clinical thrombotic risk factors and preventive treatments in antiphospholipid syndrome. Rheumatology (Oxford) 41:924-929
31. Espinola RG, Pierangeli SS, Ghara AE, Harris EN (2002) Hydroxychloroquine reverses platelet activation induced by human IgG antiphospholipid antibodies. Thromb Haemost 87:518-522
32. Feldmann R, Salomon D, Saurat JH (1994) The association of the two antimalarials chloroquine and quinacrine for treatment-resistant chronic and subacute cutaneous lupus erythematosus. Dermatology 189:425-427
33. Ferrante A, Rowan-Kelly B, Seow WK, Thong YH (1986) Depression of human polymorphonuclear leucocyte function by anti-malarial drugs. Immunology 85:125-130
34. Fox RI, Dixon R, Guarrassi V, Krubel S (1996) Treatment of primary Sjogren's syndrome with hydroxychloroquine: a retrospective, open-label study. Lupus 5(Suppl 6):S31-S36
35. Fries JF, Williams CA, Ramey DR, Block DA (1993) The relative toxicity of the disease-modifying antirheumatic drugs. Arthritis Rheum 36:297-306
36. Humphreys F, Mrks JM (1988) Mepacrine and pregnancy. Br J Dermatol 118:452
37. Jancinova V, Nosal R, Drabikova K, Danihelovaa E (2001) Cooperation of chloroquine and blood platelets in inhibition of polymorphonuclear leukocyte chemiluminescence. Biochem Pharmacol 62:1629-636
38. Jeong JY, Choi JW, Jeon KI, Jue DM (2002) Chloroquine decreases cell-surface expression of tumour necrosis factor receptors in human histiocytic U-937 cells. Immunology 105:83-91
39. Jessop S, Whitelaw D, Jordaan F (2004) Drugs for discoid lupus erythematosus (Cochrane Review). In: The Cochrane Library, Issue 2, Chichester, UK, Y. Wiley & Sons Ltd.
40. Jewell ML, McCauliffe DP (2000) Patients with cutaneous lupus erythematosus who smoke are less responsive to antimalarial treatment. J Am Acad Dermatol 42:983-987
41. Johansen PB, Gran JT (1998) Ototoxicity due to hydroxychloroquine: report of two cases. Clin Exp Rheumatol 16:472-474
42. Jones SK (1999) Ocular toxicity and hydroxychloroquine: guidelines for screening. Br J Dermatol 140:3-7
43. Jordan P, Brookes JG, Nikolic G, Le Couteur DG (1999) Hydroxychloroquine overdose: toxicokinetics and management. J Toxicol Clin Toxicol 37:861-864
44. Khoury H, Trinkaus K, Zhang MJ, Adkins D, Brown R, Vij R, Goodnough LT, Ma MK, McLeod HL, Shenoy S, Horowitz M, Dispersio JF 2003 Hydroxychloroquine for the prevention of acute graft-versushost disease after unrelated donor transplantation. Biol Blood Marrow Transplant 9:714-721
45. Klinger G, Morad Y, Westall CA, Laskin C, Spitzer KA, Koren G, Ito S, Buncic RJ (2001) Ocular toxicity and antenatal exposure to chloroquine or hydroxychloroquine for rheumatic diseases. Lancet 358:813-814
46. Krishna S, White NJ (1996) Pharmacokinetics of quinine, chloroquine and amodiaquine. Clinical implications. Clin Pharmacokin 30:263-299
47. Kuhn A, Richter-Hintz D, Oslislo C, Ruzicka T, Megahed M, Lehmann P (2000) Lupus erythematosus tumidus - a neglected subset of cutaneous lupus erythematosus: report of 40 cases. Arch Dermatol 136:1033-1041
48. Laaksonen AL, Koskiahde V, Juva K (1974) Dosage of antimalarial drugs for children with juvenile rheumatoid arthritis and systemic lupus erythematosus. Scand J Rheumatol 3:103-109
49. Leigh JM, Kennedy C T C, Ramsey JD, Henderson WJ (1979) Mepacrine pigmentation in systemic lupus erythematosus. Br J Dermatol 101:147-153
50. Levy GD, Munz SJ, Paschal J (1997) Incidence of hydroxychloroquine retinopathy in 1207 patients in a large multicentre outpatient practice. Arthritis Rheum 40:1482-1486
51. Levy RA, Vilela VS, Cataldo MJ, Ramos RC, Duarte JL, Tura BR, Albuquerque EM, Jesus NR (2001) Hydroxychloroquine (HCQ) in lupus pregnancy: double-blind and placebo-controlled study. Lupus 10:401-404
52. Liu ST, Wang CR, Yin GD, Liu MF, Lee GL, Chen MY, Chuang CY, Chen CY (2001) Hydroxychloroquine sulphate inhibits in vitro apoptosis of circulating lymphocytes in patients with systemic lupus erythematosus. Asian Pac J Allergy Immunol 19:29-35
53. Loudon JR (1988) Hydroxychloroquine and postoperative thromboembolism after total hip replacement. Amer J Med 85(Suppl 4a):57-61
54. Mackenzie AH (1983) Dose refinements in long-term therapy of rheumatoid arthritis with antimalarials. Am J Med 75(Suppl):40-45
55. Makin AJ, Wendon J, Fitt S, Portmann BC, Williams R (1994) Fulminant hepatic failure secondary to hydroxychloroquine. Gut 35:569-570
56. Maksymowych W, Russell AS (1987) Antimalarials in rheumatology: efficacy and safety. Semin Arthritis Rheum 16:206-221
57. Malcangi G, Fraticelli P, Palmieri C, Cappelli M, Danieli MG (2000) Hydroxychloroquine-induced seizure in a patient with systemic lupus erythematosus. Rheumatol Int 20:31-33
58. Marquardt K, Albertson TE (2001) Treatment of hydroxychloroquine overdose. Am J Emerg Med 19:420-424
59. Mavrikakis I, Sfikakis PP, Mavrikakis E, Rougas K, Nikolaou A, Kostopoulos C, Mavrikakis M (2003) The incidence of irreversible retinal toxicity in patients treated with hydroxychloroquine: a reapparaisal. Ophthalmology 110:1321-1326
60. McDuffie FC (1965) Bone marrow depression after drug therapy in patients with systemic lupus erythematosus. Ann Rheum Dis 24:289-292
61. Meinao IM, Sato EI, Andrade LE, Ferraz MB, Atra E (1996) Controlled trial with chloroquine diphosphate in systemic lupus erythematosus. Lupus 5:237-241
62. Metayer I, Balguerie X, Courville P, Lauret P, Joly P (2001) Photodermatosis induced by hydroxychloroquine: 4 cases. Ann Dermatol Venereol 128:729-731
63. Miller DR, Fiechtner JJ, Carpenter JR, Brown RR, Stroshane RM, Stecher VJ (1987) Plasma hydroxychloroquine concentrations and efficacy in rheumatoid arthritis. Arthritis Rheum 30:567-571
64. Minzi OM, Rais M, Svensson JO, Gustafsson LL, Ericsson O (2003) High-performance liquid chromatographic method for determination of amodiaquine, chloroquine and their monodesethyl metabolites in biological samples. J Chromatogr B Analyt Technol Biomed Life Sci 783:473-480
65. Mitja K, Izidor K, Music E (2000) Chloroquine-induced drug hypersensitivity alveolitis. Pneumologie 54:395-397
66. Molad Y, Gorshtein A, Wysenbeek AJ, Guedj D, Majadla R, Weinberger A, Amit-Vazina M (2002) Protective effect of hydroxychloroquine in systemic lupus erythematosus. Prospective long-term study of an Israeli cohort. Lupus 11:356-361
67. Morgan KW, Callen JP (2001) Calcifying lupus panniculitis in a patient with subacute cutaneous lupus erythematosus: response to diltiazem and chloroquine. J Rheumatol 28:2129-2132
68. Murphy M, Carmichael AJ (2001) Fatal toxic epidermal necrolysis associated with hydroxychloroquine. Clin Exp Dermatol 26:457-458
69. Nguyen K, Washenik K, Shupack J (2002) Necrobiosis lipoidica diabeticorum treated with chloroquine. J Am Acad Dermatol 45:S34-36
70. [No authors listed] (1995) A randomized trial of hydroxychloroquine in early rheumatoid arthritis: the HERA study. Amer J Med 98:156-168
71. Nord JE, Shah PK, Rinaldi RZ, Weisman MH (2004) Hydroxychloroquine cardiotoxicity in systemic lupus erythematosus: a report of 2 cases and review of the literature. Semin Arthritis Rheum 33:336-351
72. Ochsendorf FR, Runne U (1991) Chloroquin und Hydroxychloroquin: Nebenwirkungsprofil wichtiger Therapeutika. Hautarzt 42:140-146
73. Ochsendorf FR, Runne U (1991) Subakute Chloroquin-Überdosierung: Schwindel, körperliche Schwäche, bullöse Lichtreaktion, Sehstörungen und generalisierte Weißfärbung der Haare. Dtsch med Wschr 116:1513-1516
74. Ochsendorf FR, Runne U, Goerz G, Zrenner E (1993) Chloroquin- Retinopathie: durch individuelle Tagesdosis vermeidbar. Dtsch Med Wochenschr 118:1895-1898
75. Ochsendorf FR, Runne U (1997) Therapie des systemischen Lupus erythematodes. Dtsch Med Wochenschr 122:877
76. O'Dell JC, Haire C, Erikson N, Drymalski W, Palmer W, Eckhoff J, Garwood V, Maloley P, Klassen L, Wees S, Klein H, Moore G 1996 Treatment of rheumatoid arthritis with methotrexate alone, sulfasalazine and hydroxychloroquine or a combination of all three medications. New Engl J Med 344:1287-1291
77. O'Dell JR, Leff R, Paulsen G, Haire C, Mallek J, Eckhoff PJ, Fernandez A, Blakely K, Wees S, Stoner J, Hadley S, Felt J, Palmer W, Waytz P, Churchill M, Klassen L, Moore G 2002 Treatment of rheumatoid arthritis with methotrexate and hydroxychloroquine, methotrexate and sulfasalazine, or a combination of the three medications: results of a two-year, randomized, double-blind, placebocontrolled trial. Arthritis Rheum 46:1164-1170
78. Onigbogi O, Ajayi AA, Ukponmwan OE (2000) Mechanisms of chloroquine-induced body-scratching behavior in rats: evidence of involvement of endogenous opioid peptides. Pharmacol Biochem Behav 65:333-337
79. Onyeji CO, Ogunbona FA (2001) Pharmacokinetic aspects of chloroquine-induced pruritus: influence of dose and evidence for varied extent of metabolism of the drug. Eur J Pharm Sci 13:195-201
80. Orteu CH, Buchanan JA, Hutchison I, Leigh IM, Bull RH (2001) Systemic lupus erythematosus presenting with oral mucosal lesions: easily missed? Br J Dermatol 144:1219-1223
81. Ostensen M, Ramsey-Goldman R (1998) Treatment of inflammatory rheumatic disorders in pregnancy: what are the safest treatment options? Drug Saf 19:389-410
82. Parke AL, West B (1996) Hydroxychloroquine in pregnant patients with SLE. J Rheumatol 23:1715-1718
83. Petri M (1996) Hydroxychloroquine use in the Baltimore lupus cohort. Effects on lipids, glucose and thrombosis. Lupus 5(Suppl 1):S16-S22
84. Pinckers A, Broekhuyse RM (1983) The EOG in rheumatoid arthritis. Acta Ophthalmol 61:831-837
85. Rahman P, Gladman DD, Urowitz MB, Yuen K, Hallett D, Bruce IN (1999) The cholesterol lowering effect of antimalarial drugs is enhanced in patients with lupus taking corticosteroid drugs. J Rheumatol 26:325-330
86. Reeves GE, Boyle MJ, Bonfield J, Dobson P, Loewenthal M (2004) Impact of hydroxychloroquine therapy on chronic urticaria: chronic autoimmune urticaria study and evaluation. Intern Med J 34:182-186
87. Reuss-Borst M, Berner B, Wulf G, Muller GA (1999) Complete heart block as a rare complication of treatment with chloroquine. J Rheumatol 26:1394-1395
88. Rigaudiere F, Ingster-Moati I, Hache JC, Leid J, Verdet R, Haymann P, Rigolet MH, Zanlonghi X, Defoort S, Le Gargasson JF 2004 Up-dated ophthalmological screening and follow-up management for long-term antimalarial treatment. J Fr Ophthalmol 27:191-199
89. Ruiz-Irastorza G, Khamashta MA, Hughes GR (2000) Therapy of systemic lupus erythematosus: new agents and new evidence. Expert Opin Investig Drugs 9:1581-1593
90. Runne U, Ochsendorf FR, Schmid K, Raudonat HW (1992) Sequential concentration of chloroquine in human hair correlates with ingested dose and duration of therapy. Acta Derm Venereol (Stockh) 72:355-357
91. Savarino A, Gennero L, Sperber K, Boelaert JR (2001) The anti-HIV-1 activity of chloroquine. J Clin Virol 20:131-135
92. Scherbel AL, Mackenzie AH, Nousek JE, Adtjian M (1965) Ocular Lesions in Rheumatoid Arthritis and Related Disorders with Particular Reference to Retinopathy. N Engl J Med 273:360-366
93. Sontheimer RD (2000) Questions answered and a $1 million question raised concerning lupus erythematosus tumidus: is routine laboratory surveillance testing during treatment with hydroxychloroquine for skin disease really necessary. Arch Dermatol 136:1044-1049
94. Stein M, Bell MJ, Ang LC (2000) Hydroxychloroquine neuromyotoxicity. J Rheumatol 27:2927-2931
95. Tam LS, Gladman DD, Hallett DC, Rahman P, Urowitz MB (2000) Effect of antimalarial agents on the fasting lipid profile in systemic lupus erythematosus. J Rheumatol 27:2142-2145
96. Tett SE, McLachlan AJ, Cutler DJ, Day RO (1994) Pharmacokinetics and pharmacodynamis of hydroxychloroquine enantiomers in patients with rheumatoid arthritis receiving multiple doses of racemate. Chirality 6:355-359
97. Toubi E, Rosner I, Rozenbaum M, Kessel A, Golan TD (2000) The benefit of combining hydroxychloroquine with quinacrine in the treatment of SLE patients. Lupus 9:92-95
98. Tsakonas E, Joseph L, Esdaile JM, Choquette D, Senecal JL, Cidicino A, Danoff D, Osterland CK, Yeadon C, Smith CD (1998) A long-term study of hydroxychloroquine withdrawal on exacerbations in systemic lupus erythematosus. The Canadian hydroxychloroquine study group. Lupus 7:80-85
99. Urowitz M, Gladman D, Bruce I (2000) Atherosclerosis and systemic lupus erythematosus. Curr Rheumatol Rep 2:19-23
100. Versapuech J, Beylot-Barry M, Doutre MS, Beylot C (2000) Subacute cutaneous lupus. Evolutive and therapeutic features of a series of 24 cases. Presse Med 29:1596-1599
101. von Schmiedeberg S, Ronnau AC, Schuppe HC, Specker C, Ruzicka T, Lehmann P (2000) Combination of antimalarial drugs mepacrine and chloroquine in therapy refractory cutaneous lupus erythematosus. Hautarzt 51:82-85
102. Walker O, Ademowo OG (1996) A rapid, cost-effective liquid- chromatographic method for the determination for chloroquine and desethylchloroquine in biological fluids. Therap Drug Monitor 1:92-96
103. Wallace DJ (1989) The use of quinacrine (Atabrine) in rheumatic diseases: a reexamination. Semin Arthritis Rheum 18:282-296
104. Wallace DJ, Linker-Israeli M, Methger AL, Stecher VM (1993) The relevance of antimalarial therapy with regard to thrombosis, hypercholesterolemia and cytokines in SLE. Lupus 2(Suppl 1):S13-S15
105. Wallace DJ (1996) The use of chloroquine and hydroxychloroquine for non-infectious conditions other than rheumatoid arthritis or lupus: a critical review. Lupus 5(Suppl 1):S59-S64
106. Wallace DJ (2000) Is there a role for quinacrine (Atabrine) in the new millennium? Lupus 9:81-82
107. Weber F, Schmuth M, Fritsch P, Sepp N (2001) Lymphocytic infiltration of the skin is a photosensitive variant of lupus erythematosus: evidence by phototesting. Br J Dermatol 144:292-296
108. Wechsler B, Le Thi Huong D, Piette JC (1999) Pregnancy and systemic lupus erythematosus. Ann Med Interne (Paris) 150:408-418
109. Williams HJ, Egger MJ, Szinger JZ, Willkens RF, Kalunian KC, Clegg DO, Skosey JL, Brooks RH, Alarcon GS, Steen VD, Polisson RP, Ward JR 1994 Comparison of hydroxychloroquine and placebo in the treatment of the arthropathy of mild systemic lupus erythematosus. J Rheumatol 21:1457-1462
110. Wollheim FA, Hanson A, Laurell CB (1978) Chloroquine treatment in rheumatoid arthritis. Scand J Rheumatol 7:171-176
111. Zeidler GS (1995) Chloroquin (ResochinR) Synoptische Darstellung eines Pharmakons und seiner Indikation in der Medizin, speziell in der Dermatologie. In: Hautklinik. Düsseldorf: Heinrich-Heine University, Inaugural Dissertation
112. Ziering CL, Rabinowith LG, Esterly NB (1993) Antimalarials for children: indications, toxicities, and guidelines. J Am Acad Dermatol 28:764-770